|
|
Article: Collegium Acquires Tri-Nasal Nasal Spray for Allergic Rhinitis from Muro Pharmaceutical.
- Article from:
- Business Wire
- Article date:
- October 7, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
CUMBERLAND, R.I.--(BUSINESS WIRE)--Oct. 7, 2003
Collegium Pharmaceutical, Inc., a closely held specialty pharmaceutical company, today announced that it has acquired from Muro Pharmaceutical, Inc., all rights to Tri-Nasal(R) (triamcinolone acetonide, USP) Nasal Spray, including the product's approved NDA and the right to market the product. This product expands Collegium's current portfolio of respiratory products that includes a patent pending formulation of anti-histamines. Muro received U.S. FDA approval of Tri-Nasal in 2000 as a once-daily, intranasal steroid medication for the treatment of ...